Why Do Patients With Atrial Fibrillation Not Receive Warfarin?

摘要: Atrial fibrillation (AF) is a growing public health problem associated with significant morbidity and mortality. Numerous randomized controlled trials of warfarin have conclusively demonstrated that long-term anticoagulation therapy can reduce the risk for stroke by approximately 68% per year in patients nonvalvular AF, even more valvular AF. However, available data show those AF no contraindication to therapy, only 15% 44% are prescribed warfarin. Our literature review has identified patient-, physician-, care system‐related barriers prescription. relative importance these specific remains unknown. Further work needed understand discrepancy between trial evidence clinical practice patterns. Arch Intern Med. 2000;160:41-46